| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2024 | HUMAN CELL CO | 1701 QUINCY AVE STE 21 | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R43EY036298 | Topical treatment of an optimized NGF for Dry Eye | 000 | 1 | NIH | 11/7/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,717,417 ) |
| | 2024 | 2024 | HUMAN CELL CO | 1701 QUINCY AVE | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R44EY028058 | Optimizing NGF for Topical Treatment of Glaucoma | 001 | 3 | NIH | 8/7/2024 | $991,520 |
| | 2024 | 2024 | HUMAN CELL CO | 1701 QUINCY AVE STE 21 | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R43EY036298 | Topical treatment of an optimized NGF for Dry Eye | 000 | 1 | NIH | 9/12/2024 | $365,000 |
| | 2024 | 2024 | HUMAN CELL CO | 1701 QUINCY AVE STE 21 | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R43EY036753 | Topical NGF Therapy and oral nicotinamide supplementation for Glaucoma | 000 | 1 | NIH | 9/6/2024 | $360,897 |
| | 2024 | 2023 | HUMAN CELL CO | 1701 QUINCY AVE | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R44EY028058 | Optimizing NGF for Topical Treatment of Glaucoma | 000 | 2 | NIH | 10/16/2023 | $0 |
| | 2024 | 2021 | HUMAN CELL CO | 1701 QUINCY AVE STE 21 | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R43NS122551 | tPA and NGF therapy for stroke | 000 | 1 | NIH | 4/8/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $1,381,060 ) |
| | 2023 | 2023 | HUMAN CELL CO | 1701 QUINCY AVE | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R43CA275458 | Optimization of TIL Cell Manufacturing for Cancer Treatment | 000 | 1 | NIH | 2/17/2023 | $400,000 |
| | 2023 | 2023 | HUMAN CELL CO | 1701 QUINCY AVE | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R44EY028058 | Optimizing NGF for Topical Treatment of Glaucoma | 000 | 2 | NIH | 8/24/2023 | $981,060 |
|
| Issue Date FY: 2022 ( Subtotal = $0 ) |
| | 2022 | 2021 | HUMAN CELL CO | 1701 QUINCY AVE STE 21 | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R43NS122551 | tPA and NGF therapy for stroke | 000 | 1 | NIH | 10/26/2021 | $0 |
|
| Issue Date FY: 2021 ( Subtotal = $359,500 ) |
| | 2021 | 2021 | HUMAN CELL CO | 1701 QUINCY AVE STE 21 | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R43NS122551 | tPA and NGF therapy for stroke | 000 | 1 | NIH | 9/17/2021 | $359,500 |
| | 2021 | 2017 | HUMAN CELL CO | 1701 QUINCY AVE STE 21 | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R43EY028058 | Optimizing NGF for Topical Treatment of Glaucoma | 000 | 1 | NIH | 5/3/2021 | $0 |
| | 2021 | 2017 | HUMAN CELL CO | 1701 QUINCY AVE STE 21 | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R43HL139105 | Recombinant Prothrombin Therapy for Hemorrhage | 000 | 1 | NIH | 2/19/2021 | $0 |
|
| Issue Date FY: 2019 ( Subtotal = $0 ) |
| | 2019 | 2017 | HUMAN CELL CO | 1701 QUINCY AVE STE 21 | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R43HL139105 | Recombinant Prothrombin Therapy for Hemorrhage | 000 | 1 | NIH | 8/19/2019 | $0 |
| | 2019 | 2017 | HUMAN CELL CO | 1701 QUINCY AVE STE 21 | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R43EY028058 | Optimizing NGF for Topical Treatment of Glaucoma | 000 | 1 | NIH | 8/13/2019 | $0 |
|
| Issue Date FY: 2017 ( Subtotal = $599,380 ) |
| | 2017 | 2017 | HUMAN CELL CO | 1701 QUINCY AVE STE 21 | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R43EY028058 | Optimizing NGF for Topical Treatment of Glaucoma | 000 | 1 | NIH | 6/29/2017 | $299,805 |
| | 2017 | 2017 | HUMAN CELL CO | 1701 QUINCY AVE STE 21 | NAPERVILLE | IL | 60540-6685 | DUPAGE | USA | R43HL139105 | Recombinant Prothrombin Therapy for Hemorrhage | 000 | 1 | NIH | 8/10/2017 | $299,575 |
|
|
